Board of Directors

Mathias Uhlén, Ph.D.

Chairman
Dr Uhlén is co-founder of Atlas Antibodies AB, and Professor of Biotechnology at the Royal Institute of Technology in Stockholm. Dr Uhlén is Program Director of the Human Protein Atlas program. Dr Uhlén is member of the Board of Directors of Biotage AB (publ), Skanditek AB (publ), Nordiag ASA (publ), Novozymes A/S (publ), Affibody AB, KTH Holding AB and SweTree Genomics AB.

Marianne Hansson, Ph.D.

Chief Executive Officer
Dr Hansson is co-founder of Atlas Antibodies AB. Dr Hansson has a research background in biotechnology and more than 8 years experience in marketing and business development, most recently from Affibody AB. Dr Hansson earned her PhD from the Royal Institute of Technology.

Torben Jørgensen

Board member
Mr Jørgensen is CEO and President of Biotage AB. Mr Jørgensen has more than 10 years of experience from sales and marketing of antibody research reagents and diagnostic products as CEO of the Danish company Dako AS between 1989 and 1999. Mr Jørgensen was CEO of Karo Bio 2000 to 2001 and CEO of Affibody AB from 2001 to 2005. Mr Jørgensen is member of the Board of Directors of MIP Technologies.

Jakob Lindberg

Board member
Mr Lindberg is Vice President at Investor Growth Capital. Mr Lindberg is a member of the Board of Directors of Cellectricon AB, Scibase AB, Sidec AB, Swedish Orphan International AB and Åmic AB.

Fredrik Pontén, M.D., Ph.D.

Board member
Dr Pontén is co-founder of Atlas Antibodies AB, and Professor and board-certified specialist of pathology at the Uppsala University Hospital. Dr Pontén is Vice Program Director for the Human Protein Atlas program and responsible for the Uppsala site.